4D-125 IVT Injection

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

4mo

FDMTPhase 2$1.0B

4D-125 IVT Injection Phase 2 Results Expected

4D-125 IVT Injection• X-Linked Retinitis Pigmentosa21

Jun 15Estimated

00%

Competitive Landscape

0 competitors in X-Linked Retinitis Pigmentosa

Drug Information

Target Indication

X-Linked Retinitis Pigmentosa

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

FDMT

4D Molecular Therapeutics, Inc.

Related Pipeline

Macular Neovascularization Secondary to Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular (Wet) Age-Related Macular Degeneration

Diabetic Macular Edema

Fabry Disease